Not out of the woods yet for Alzheimer’s mAbs: a Perspective

Alzheimer’s therapy Leqembi is being used according to its label and without a spike in adverse events over the rates observed in clinical trials, according to presenters at this week’s CTAD meeting. While that’s encouraging, the true test of appropriate use and safety in the real world may be yet to come.

Two messages were loud and clear at the meeting. Physicians are successfully managing the complex treatment protocol required for Leqembi lecanemab, and the small fraction of patients receiving the drug skew heavily urban and White. An analysis of claims data on 3,155 patients, presented by Marwan Sabbagh of the Barrow Neurological Institute, found 93.3% were urban and 84.3% White. ...